6 unchanged sentences
001-33038, filed July 1, 2016).
−Removed: Second Amendment to Patent License Agreement, dated as of September 28, 2020, by and between the Registrant and the National Cancer Institute.
−Removed: Amendment No.
−Removed: 1 to the Exclusive License Agreement by and between the Registrant and PGEN Therapeutics, Inc.
−Removed: (formerly known as Precigen, Inc.), dated October 15, 2020.
+Added: Agreement, by and among the Registrant, WaterMill Asset Management Corp.
+Added: and Robert W.
+Added: Postma, dated February 4, 2021 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, SEC File No.
+Added: 001-33038, filed February 23, 2021).
+Added: Consulting Agreement by and between the Registrant and Danforth Advisors LLC, effective as of January 21, 2021 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, SEC File No.
+Added: 001-33038, filed February 5, 2021).
+Added: Employment Agreement by and between Registrant and Heidi Hagen, dated February 25, 2021 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, SEC File No.
+Added: 001-33038, filed March 2, 2021).
Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14 or 15d-14 under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
11 unchanged sentences
This certification is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
−Removed: Certain portions of this exhibit (indicated by asterisks) have been omitted because they are not material and would likely cause competitive harm to Ziopharm Oncology, Inc.
−Removed: if publicly disclosed.
+Added: Indicates a management contract or compensatory plan.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ZIOPHARM ONCOLOGY, INC.
−Removed: /s/ Laurence J.N.
−Removed: Laurence J.N.
−Removed: Cooper, M.D., Ph.D.
−Removed: Chief Executive Officer
+Added: /s/ Heidi Hagen
+Added: Interim Chief Executive Officer
(On Behalf of the Registrant and as Principal Executive Officer)
−Removed: November 5, 2020
−Removed: /s/ Satyavrat Shukla
−Removed: Satyavrat Shukla
−Removed: Executive Vice President and Chief Financial Officer
+Added: /s/ Timothy Cunningham
+Added: Timothy Cunningham
+Added: Interim Chief Financial Officer
(Principal Financial Officer)
−Removed: November 5, 2020
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.